Today, cancer of the prostate is considered highly treatable. The effects of prostate cancer treatment can however by considerable for some patients — particularly for those who have undergone invasive procedures such as radiotherapy or the radical removal of the prostate. Therefore, new medical treatment methods focus primarily on reducing the undesirable side effects of prostate cancer therapy and aim to help minimize impotence and incontinence, which commonly occur in invasive procedures. One such method is TULSA, a new treatment that uses ultrasound to treat the prostate.
Following prostate surgery or radiotherapy, patients may experience symptoms such as incontinence, impotence or a burning sensation when urinating. Impotence can be particularly traumatic for younger patients. Patients with prostate cancer are living longer thanks to advancements intherapies, as such, the German Cancer Society is encouraging patients with a localized tumour to start thinking about life post-therapy before they select their treatment. Despite major medical advances in the fields of radiotherapy and surgical techniques, the German Cancer Society indicates that 20 to 80 percent of patients suffer from erectile dysfunction following a radical prostatectomy, and between 25 and 60% for those treated with radiotherapy.  These side effects often improve over time, but in the case of permanent impairment, medication, mechanical procedures or a penile prosthesis may be need to be considered.
One new prostate cancer treatment, which has grown in adoption within Germany, is known as TULSA. Clinical studies have shown that the TULSA procedure can minimize unwanted side effects such as impotence and urinary incontinence, which may severely impact a patients’ quality of life following treatment. The TULSA method uses MRI-guided transurethral ultrasound to heat and coagulate the cancerous tissue in a precise and targeted manner. The surrounding tissue, which is important for maintaining the patient’s quality of life, is therefore largely protected. The TULSA procedure can be used in patients with localized prostate cancer and a Gleason score of 6 and 7.